Scholarlink

Purpose <p>To evaluate the feasibility, safety, and efficacy of image-guided percutaneous cryoablation for the treatment of soft-tissue metastatic tumours in patients with oligoprogressive disease.</p> Methods <p>Consecutive patients undergoing percutaneous cryoablation between March 2017 and December 2024 were identified from a prospectively maintained database. Patient demographics, disease characteristics, procedural details, and outcomes were recorded. The Kaplan–Meier method was used to calculate local tumour progression-free survival (LTPFS), progression-free survival (PFS), and overall survival (OS). Technical success, technique efficacy, complications, and oncologic outcomes were analysed. The primary endpoints were technical success, major complications, LTPFS, and PFS. The secondary endpoint was OS.</p> Results <p>Fifty-two metastatic tumours (median size: 20&#xa0;mm [interquartile range, 12–36&#xa0;mm]) were treated across 46 sessions in 38 patients. The technical success rate (defined as complete tumour coverage by the ablation zone with a 5-mm margin) was 100%, with 4% major complications (CTCAE grade ≥ 3). Eleven tumours were treated with palliative intent, while 41 were treated for local tumour control.</p> <p>Residual unablated tumour was observed at first follow-up imaging in 7% of cases. Local tumour progression occurred in 20% during the follow-up period. The 2-year LTPFS was 76%. The 2-year PFS was 27%, with a median PFS of 5.8&#xa0;months. The 2-year OS was 68%.</p> Conclusion <p>Image-guided percutaneous cryoablation of soft-tissue metastases in oligoprogressive disease is technically feasible, safe, and effective for achieving local control. Prospective controlled studies are warranted to further define its role within the evolving oncologic treatment paradigm.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Image-guided cryoablation of soft-tissue metastases in patients with oligoprogressive disease: analysis of feasibility, safety, and efficacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月31日

查看全文
  • Nicos Fotiadis,
  • Niaz Ahmed,
  • Edward W. Johnston,
  • Naureen Starling,
  • Robin Jones,
  • Andrew Hayes,
  • Sanjay Popat,
  • David Cunningham,
  • Paris Tekkis

摘要

Purpose

To evaluate the feasibility, safety, and efficacy of image-guided percutaneous cryoablation for the treatment of soft-tissue metastatic tumours in patients with oligoprogressive disease.

Methods

Consecutive patients undergoing percutaneous cryoablation between March 2017 and December 2024 were identified from a prospectively maintained database. Patient demographics, disease characteristics, procedural details, and outcomes were recorded. The Kaplan–Meier method was used to calculate local tumour progression-free survival (LTPFS), progression-free survival (PFS), and overall survival (OS). Technical success, technique efficacy, complications, and oncologic outcomes were analysed. The primary endpoints were technical success, major complications, LTPFS, and PFS. The secondary endpoint was OS.

Results

Fifty-two metastatic tumours (median size: 20 mm [interquartile range, 12–36 mm]) were treated across 46 sessions in 38 patients. The technical success rate (defined as complete tumour coverage by the ablation zone with a 5-mm margin) was 100%, with 4% major complications (CTCAE grade ≥ 3). Eleven tumours were treated with palliative intent, while 41 were treated for local tumour control.

Residual unablated tumour was observed at first follow-up imaging in 7% of cases. Local tumour progression occurred in 20% during the follow-up period. The 2-year LTPFS was 76%. The 2-year PFS was 27%, with a median PFS of 5.8 months. The 2-year OS was 68%.

Conclusion

Image-guided percutaneous cryoablation of soft-tissue metastases in oligoprogressive disease is technically feasible, safe, and effective for achieving local control. Prospective controlled studies are warranted to further define its role within the evolving oncologic treatment paradigm.